Integrins in glioblastoma: Still an attractive target?

Pharmacological Research

Volumn 113, Issue , 2016, Pages 55-61

  Paolillo, Mayra ^a   Serra, Massimo ^a   Schinelli, Sergio ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

EMT; Glioblastoma stem cells; Periostin; RGD integrins; TGF ; Tumor niche

Indexed keywords

1A ARGINYLGLYCYLASPARTIC ACID; ANTINEOPLASTIC AGENT; ARGINYLGLYCYLASPARTIC ACID; CILENGITIDE; CYCLO DIKETOPIPERAZINE 3 ARGINYLGLYCYLASPARTIC ACID; CYCLO DIKETOPIPERAZINE 3 ISO ASPARTYLGLYCYLARGININE; GLPG 0187; INTEGRIN; INTEGRIN RECEPTOR; K 34C; SJ 749; SMALL MOLECULE INTEGRIN ANTAGONIST; TEMOZOLOMIDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR;

ADJUVANT THERAPY; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BRAIN BLOOD VESSEL; CANCER ASSOCIATED FIBROBLAST; DRUG EFFICACY; DRUG STRUCTURE; ENDOTHELIUM CELL; EPITHELIAL MESENCHYMAL TRANSITION; FIBROBLAST; GLIOBLASTOMA; GLIOMA CELL; HUMAN; NONHUMAN; PERICYTE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN FUNCTION; REVIEW; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; ANIMAL; BRAIN TUMOR; GLIOMA; METABOLISM; PATHOLOGY; PHYSIOLOGY; SIGNAL TRANSDUCTION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; EPITHELIAL-MESENCHYMAL TRANSITION; GLIOBLASTOMA; GLIOMA; HUMANS; INTEGRINS; SIGNAL TRANSDUCTION;

EID: 84982170293     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2016.08.004     Document Type: Review

References (63)

1. [1] Piccirillo, S.G., Combi, R., Cajola, L., Patrizi, A., Redaelli, S., et al. Distinct pools of cancer stem-like cells coexist within human glioblastomas and display different tumorigenicity and independent genomic evolution. Oncogene 28 (2009), 1807–1811.
2. [2] Singh, S.K., Hawkins, C., Clarke, I.D., Squire, J.A., Bayani, J., et al. Identification of human brain tumour initiating cells. Nature 432 (2004), 396–401.
3. [3] Eramo, A., Ricci-Vitiani, L., Zeuner, A., Pallini, R., Lotti, F., et al. Chemotherapy resistance of glioblastoma stem cells. Cell Death Differ. 13 (2006), 1238–1241.
4. [4] Kang, S.K., Tumorigenesis of chemotherapeutic drug-resistant cancer stem-like cells in brain glioma. Stem Cells Dev. 16 (2007), 837–847.
5. [5] Liu, G., Yuan, X., Zeng, Z., Tunici, P., Ng, H., et al. Analysis of gene expression and chemoresistance of cd133+ cancer stem cells in glioblastoma. Mol. Cancer, 5, 2006, 67.
6. [6] Meldolesi, J., Pharmacology of the cell/matrix form of adhesion. Pharm. Res. 107 (2016), 430–436.
7. [7] Paolillo, M., Russo, M.A., Serra, M., Colombo, L., Schinelli, S., Small molecule integrin antagonists in cancer therapy. Mini Rev. Med. Chem. 9 (2009), 1439–1446.
8. [8] Tucker, G.C., Integrins: molecular targets in cancer therapy. Curr. Oncol. Rep. 8 (2006), 96–103.
9. [9] Niibori-Nambu, A., Midorikawa, U., Mizuguchi, S., Hide, T., Nagai, M., Glioma initiating cells form a differentiation niche via the induction of extracellular matrices and integrin αV. PLoS One, 8, 2013, 10.1371/journal.pone.0059558.
10. [10] Seguin, L., Desgrosellier, J.S., Weis, S.M., Cheresh, D.A., Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 25 (2015), 234–240.
11. [11] Mas-Moruno, C., Rechenmacher, F., Kessler, H., Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med. Chem. 10 (2010), 753–768.
12. [12] Lindsey, S., Langhans, S.A., Crosstalk of oncogenic signaling pathways during epithelial-mesenchymal transition. Front. Oncol., 4, 2014, 358.
13. [13] Papageorgis, P., TGFβ signaling in tumor initiation, epithelial-to-mesenchymal transition, and metastasis. J. Oncol., 2015, 10.1155/2015/587193.
14. [14] Peñuelas, S., Anido, J., Prieto-Sánchez, R.M., Folch, G., Barba, I., et al. TGF-beta increases glioma-initiating cell self-renewal through the induction of LIF in human glioblastoma. Cancer Cell 15 (2009), 315–327.
15. [15] Anido, J., Sáez-Borderías, A., Gonzàlez-Juncà, A., Rodón, L., Folch, G., et al. TGF-β receptor inhibitors target the CD44(high)/Id1(high) glioma-initiating cell population in human glioblastoma. Cancer Cell 18 (2010), 655–668, 10.1016/j.ccr.2010.10.023.
16. [16] Wipff, P.J., Hinz, B., Integrins and the activation of latent transforming growth factor beta1 – an intimate relationship. Eur. J. Cell Biol. 87 (2008), 601–615.
17. [17] Ludbrook, S.B., Barry, S.T., Delves, C.J., Horgan, C.M., The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3. Biochem. J. 369 (2003), 311–318.
18. [18] Sheppard, D., Integrin-mediated activation of latent transforming growth factor beta. Cancer Metastasis Rev. 24 (2005), 395–402.
19. [19] Tritschler, I., Gramatzki, D., Capper, D., Mittelbronn, M., Meyermann, R., et al. Modulation of TGF-beta activity by latent TGF-beta-binding protein 1 in human malignant glioma cells. Int. J. Cancer 125 (2009), 530–540.
20. [20] Frei, K., Gramatzki, D., Tritschler, I., Schroeder, J.J., Espinoza, L., et al. Transforming growth factor-β pathway activity in glioblastoma. Oncotarget 6 (2015), 5963–5977.
21. [21] Yen, S.Y., Chen, S.R., Hsieh, J., Li, Y.S., Chuang, S.E., et al. Biodegradable interstitial release polymer loading a novel small molecule targeting Axl receptor tyrosine kinase and reducing brain tumour migration and invasion. Oncogene 6 (2015), 5963–5977 10.18632/oncotarget.3467.
22. [22] Wang, J., Cazzato, E., Ladewig, E., Frattini, V., Rosenbloom, D.I.S., et al. Clonal evolution of glioblastoma under therapy. Nat. Genet. 48 (2016), 768–776, 10.1038/ng.3590.
23. [23] Massagué, J., TGFβ in cancer. Cell 134 (2008), 215–230.
24. [24] Fakhrai, H., Dorigo, O., Shawler, D.L., Lin, H., Mercola, D., et al. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc. Natl. Acad. Sci. USA 93 (1996), 2909–2914.
25. [25] Calabrese, C., Poppleton, H., Kocak, M., Hogg, T.L., Fuller, C., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11 (2007), 69–82, 10.1016/j.ccr.2006.11.020.
26. [26] Seidel, S., Garvalov, B.K., Wirta, V., von Stechow, L., Schanzer, A., et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2a. Brain 133 (2010), 983–995, 10.1093/brain/awq042.
27. [27] Xian-zong, Y., Sen-lin, X., Yan-hong, X., Shi-can, Y., Yi-fang, P., et al. Tumor-associated microglia/macrophages enhance the invasion of glioma stem-like cells via TGF-β1 signaling pathway. J. Immunol. 189 (2012), 444–453, 10.4049/jimmunol.1103248.
28. [28] Abou-Ghazal, M., Yang, D.S., Qiao, W., Reina-Ortiz, C., Wei, J., et al. The incidence correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin. Cancer Res. 14 (2008), 8228–8235.
29. [29] Zhou, W., Ke, S.Q., Huang, Z., Flavahan, W., Fang, X., et al. Periostin secreted by glioblastoma stem cells recruits M2 tumour-associated macrophages and promotes malignant growth. Nat. Cell Biol. 17 (2015), 170–182, 10.1038/ncb3090.
30. [30] Bao, S., Ouyang, G., Bai, X., Huang, Z., Ma, C., et al. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 5 (2004), 329–339.
31. [31] Malanchi, I., Santamaria-Martínez, A., Susanto, E., Peng, H., Lehr, H.A., et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 481 (2012), 85–89, 10.1038/nature10694.
32. [32] Michaylira, C.Z., Wong, G.S., Miller, C.G., Gutierrez, C.M., Nakagawa, H., et al. Periostin a cell adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a novel tumor-invasive signature in esophageal cancer. Cancer Res. 70 (2010), 5281–5292, 10.1158/0008-5472.CAN-10-0704.
33. [33] Gillan, L., Matei, D., Fishman, D.A., Gerbin, C.S., Karlan, B.Y., Chang, D.D., Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res. 62 (2002), 5358–5364.
34. [34] Butcher, J.T., Norris, R.A., Hoffman, S., Mjaatvedt, C.H., Markwald, R.R., Periostin promotes atrioventricular mesenchyme matrix invasion and remodeling mediated by integrin signaling through Rho/PI 3-kinase. Dev. Biol. 302 (2007), 256–266.
35. [35] Trylcova, J., Busek, P., Smetana, K. Jr., Balaziova, E., Dvorankova, B., et al. Effect of cancer-associated fibroblasts on the migration of glioma cells in vitro. Tumour Biol. 36 (2015), 5873–5879, 10.1007/s13277-015-3259-8.
36. [36] Chen, S.Y., Lin, J.S., Lin, H.C., Shan, Y.S., Cheng, Y.J., Yang, B.C., Dependence of fibroblast infiltration in tumor stroma on type IV collagen-initiated integrin signal through induction of platelet-derived growth factor. Biochim. Biophys. Acta 1853 (2015), 929–939.
37. [37] Filatova, A., Acker, T., Garvalov, B.K., The cancer stem cell niche(s): the crosstalk between glioma stem cells and their microenvironment. Biochim. Biophys. Acta 1830 (2013), 2496–2508.
38. [38] Desgrosellier, J.S., Cheresh, D.A., Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 10 (2010), 9–22.
39. [39] Danhier, F., Le Breton, A., Préat, V., RGD-based strategies to target alpha(v) beta(3) integrin in cancer therapy and diagnosis. Mol. Pharm. 9:2012 (2012), 2961–2973, 10.1021/mp3002733.
40. [40] Gao, H., Xiong, Y., Zhang, S., Yang, Z., Cao, S., Jiang, X., RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration. Mol. Pharm. 11 (2014), 1042–1052, 10.1021/mp400751g.
41. [41] Hurtado-Alvarado, G., Cabañas-Morales, A.M., Gómez-Gónzalez, B., Pericytes: brain-immune interface modulators. Front. Integr. Neurosci., 7, 2014, 80, 10.3389/fnint.2013.00080.
42. [42] Svensson, A., Özen, I., Genové, G., Paul, Gesine, Bengzon, J., Endogenous brain pericytes are widely activated and contribute to mouse glioma microvasculature. PLoS One, 10, 2015, 10.1371/journal.pone.0123553.
43. [43] Caspani, E.M., Crossley, P.H., Redondo-Garcia, C., Martinez, S., Glioblastoma: a pathogenic crosstalk between tumor cells and pericytes. PLoS One, 9, 2014, 10.1371/journal.pone.0101402.
44. [44] Ricci-Vitiani, L., Pallini, R., Biffoni, M., Todaro, M., Invernici, G., et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 468 (2010), 824–828, 10.1038/nature09557.
45. [45] Wang, R., Chadalavada, K., Wilshire, J., Kowalik, U., Hovinga, K.E., et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 468 (2010), 829–833, 10.1038/nature09624.
46. [46] Cheng, L., Huang, Z., Zhou, W., Wu, Q., Donnola, S., et al. Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth. Cell 153 (2013), 139–152, 10.1016/j.cell.2013.02.021.
47. [47] Svensson, A., Özen, I., Genové, G., Paul, G., Bengzon, J., Endogenous brain pericytes are widely activated and contribute to mouse glioma microvasculature. PLoS One, 10, 2015, 10.1371/journal.pone.0123553.
48. [48] Mas-Moruno, C., Rechenmacher, F., Kessler, H., Cilengitide: the first anti-angiogenic small molecule drug candidate design, synthesis and clinical evaluation. Anticancer Agents Med. Chem. 10 (2010), 753–768.
49. [49] Stupp, R., Hegi, M.E., Gorlia, T., Erridge, S.C., Perry, J., et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre randomised, open-label, phase 3 trial. Lancet Oncol. 15 (2014), 1100–1108.
50. [50] National Cancer Institute Clinical Trials, clinicaltrials.gov.
51. [51] Chinot, O.L., Cilengitide in glioblastoma: when did it fail?. Lancet Oncol. 15 (2014), 1044–1045.
52. [52] Russo, M.A., Paolillo, M., Sanchez-Hernandez, Y., Curti, D., Ciusani, E., et al. A small-molecule RGD-integrin antagonist inhibits cell adhesion, cell migration and induces anoikis in glioblastoma cells. Int. J. Oncol. 42 (2013), 83–92.
53. [53] Martinkova, E., Maglott, A., Leger, D.Y., Bonnet, D., Stiborova, M., et al. alpha5beta1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glioblastoma cells. Int. J. Cancer 127 (2010), 1240–1248.
54. [54] Smallheer, J.M., Weigelt, C.A., Woerner, F.J., Wells, J.S., Daneker, W.F., et al. Synthesis and biological evaluation of nonpeptide integrin antagonists containing spirocyclic scaffolds. Bioorg. Med. Chem. Lett. 14 (2004), 383–387.
55. [55] Heckmann, D., Meyer, A., Laufer, B., Zahn, G., Stragies, R., Kessler, H., Rational design of highly active and selective ligands for the alpha5beta1 integrin receptor. Chembiochem 9 (2008), 1397–1407.
56. [56] Arosio, D., Belvisi, L., Colombo, L., Colombo, M., Invernizzi, D., et al. A potent integrin antagonist from a small library of cyclic RGD pentapeptide mimics including benzyl-substituted azabicycloalkane amino acids. ChemMedChem 3 (2008), 1589–1603.
57. [57] Van Agthoven, J.F., Xiong, J.P., Alonso, J.L., Rui, X., Adair, B.D., et al. Structural basis for pure antagonism of integrin αVβ3 by a high-affinity form of fibronectin. Nat. Struct. Mol. Biol. 21 (2014), 383–388.
58. [58] Panzeri, S., Zanella, S., Arosio, D., Vahdati, L., Dal Corso, A., et al. Cyclic isoDGR and RGD peptidomimetics containing bifunctional diketopiperazine scaffolds are integrin antagonists. Chemistry 21 (2015), 6265–6271.
59. [59] Curnis, F., Longhi, R., Crippa, L., Cattaneo, A., Dondossola, E., et al. Spontaneous formation of L-isoaspartate and gain of function in fibronectin. J. Biol. Chem. 281 (2006), 36466–36476.
60. [60] Clarke, S., Propensity for spontaneous succinimide formation from aspartyl and asparaginyl residues in cellular proteins. Int. J. Pept. Protein Res. 30 (1987), 808–821.
61. [61] Curnis, F., Sacchi, A., Gasparri, A., Longhi, R., Bachi, A., et al. Isoaspartate-glycine-arginine: a new tumor vasculature-targeting motif. Cancer Res. 68 (2008), 7073–7082.
62. [62] Silginer, M., Weller, M., Ziegler, U., Roth, P., Integrin inhibition promotes atypical anoikis in glioma cells. Cell Death Dis., 23, 2014, 5.
63. [63] Reeves, K.J., Hurrell, J.E., Cecchini, M., van der Pluijm, G., Down, J.M., et al. Prostate cancer cells home to bone using a novel in vivo model: modulation by the integrin antagonist GLPG0187. Int. J. Cancer 136 (2015), 1731–1740.